Alnylam Pharmaceuticals company profile
Innovating RNAi therapies for a healthier tomorrow.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is at the forefront of biotechnology, specialising in the development of RNA interference therapies. Founded in 2002, the company has grown into a global leader, pioneering transformative medicines to treat rare genetic diseases, hepatic infections, and cardio-metabolic conditions. With headquarters in Cambridge, Massachusetts, Alnylam operates globally, including significant operations in the UK. Their innovative approach to tackling previously untreatable conditions places them as a trailblazer in the biotech industry. With a robust pipeline of development programmes and a commitment to rigorous science, Alnylam is poised to impact the global healthcare landscape significantly.
Industry: Biotechnology
Location: UK